bioRxivCancer Biology
A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer
Abstract
BackgroundMechanistic models of within-cell signal transduction networks can explain how these networks integrate internal and external inputs to give rise to the appropriate cellular response. These models can be fruitfully used in cancer cells, whose aberrant decision-making regarding their survival or death, proliferation or quiescence can be connected to errors in the state of nodes or edges of the signal transduction network.\n\nResultsHere we present a comprehensive network, and discrete dynamic model, of signal transduction in breast cancer based on the literature of ER+, HER2+, and PIK3CA-mutant breast cancers. The network model recapitulates known resistance mechanisms to PI3K inhibitors and suggests other possibilities for resistance. The model also reveals known and novel combinatorial interventions that are more effective than PI3K inhibition alone.\n\nConclusionsThe use of a logic-based, discrete dynamic model enables the identification of results that are mainly due to the organization of the signaling network, and those that also depend on the kinetics of individual events. Network-based models such as this will play an increasing role in the rational design of high-order therapeutic combinations.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cell line-specific network models of ER+ breast cancer identify PI3Kα inhibitor sensitivity factors and drug combinations
J. Gomez Tejeda Zanudo, P. Mao, … N. Wagle·bioRxiv·Aug 25, 2020
- SynDISCO: A Mechanistic Modeling-Based Framework for Predictive Prioritization of Synergistic Drug Combinations Directed at Cell Signaling Networks
Sung‐Young Shin, Lan K. Nguyen·bioRxiv·Apr 7, 2023
- Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer
D. Hany, M. Zoetemelk, … D. Picard·bioRxiv·Aug 30, 2022
- Modeling Breast Cancer Proliferation, Drug Synergies, and Alternating Therapies
Wei He, Diane M. Demas, … William T. Baumann·iSciencePeer-reviewed·Apr 23, 2023
- Kinome rewiring reveals AURKA is a molecular barrier to the efficacy of PI3K/mTOR-pathway inhibitors in breast cancer
H. J. Donnella, J. T. Webber, … S. Bandyopadhyay·bioRxiv·Jun 30, 2017
- Deciphering the Signaling Network Landscape of Breast Cancer Improves Drug Sensitivity Prediction
Marco Tognetti, Attila Gábor, … Bernd Bodenmiller·Cell SystemsPeer-reviewed·Apr 30, 2021